Using a proteomic approach in plasma and serum samples from NAFLD patients, Corey et al. identified circulating levels of formimidoyltransferase cyclodeaminase (FTCD) as an indicative biomarker for the NAFLD to NASH progression [27]. The gene discussed is FTCD; the disease is metabolic dysfunction-associated steatotic liver disease.